GlaxoSmithKline BENLYSTA Prescribing Information

Prescribing information for BENLYSTA (belimumab), a BLyS-specific inhibitor for SLE and lupus nephritis, covering dosage, administration, warnings, and safety.


GlaxoSmithKline BENLYSTA Prescribing Information - cover page
Brand
GLAXOSMITHKLINE
Category
Drugs
Document type
Other
Language
English
Pages
64
File format
PDF
File size
2.6 MB
Published
17 November, 2026
Updated
17 November, 2026
MD5 checksum
9ECEBA9351C0ED5D1129461EB037DDCB

About this manual

BENLYSTA (belimumab) is a B-lymphocyte stimulator (BLyS)-specific inhibitor indicated for patients 5 years of age and older with active systemic lupus erythematosus (SLE) or active lupus nephritis who are receiving standard therapy. Its efficacy has not been evaluated in patients with severe active central nervous system lupus, and use is not recommended in that situation. BENLYSTA may be administered intravenously or subcutaneously; vials are for intravenous use only, while autoinjectors and prefilled syringes are for subcutaneous use only.

The document provides recommended dosages by route and patient population, preparation and dilution instructions, contraindications, warnings and precautions, adverse reactions, and other prescribing information. Common adverse reactions include nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, pharyngitis, and injection site reactions. Serious infections, hypersensitivity reactions including anaphylaxis, depression and suicidality, and immunization precautions are addressed in the warnings and precautions.

What's inside

  • Indications and Usage
  • Dosage and Administration
  • Dosage Forms and Strengths
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Drug Interactions
  • Use in Specific Populations
  • Overdosage
  • Clinical Pharmacology

Specifications

Intravenous dosage10 mg/kg at 2-week intervals for the first 3 doses and at 4-week intervals thereafter
Intravenous infusion duration1 hour
Subcutaneous dosage, adults with SLE200 mg once weekly
Subcutaneous dosage, pediatric patients with SLE weighing at least 40 kg200 mg once weekly
Subcutaneous dosage, pediatric patients with SLE weighing 15 kg to less than 40 kg200 mg once every 2 weeks
Subcutaneous dosage, adults with lupus nephritis400 mg once weekly for 4 doses, then 200 mg once weekly thereafter
Intravenous vial strengths120 mg or 400 mg belimumab lyophilized powder
Subcutaneous injection strength200 mg/mL belimumab
Reconstituted intravenous solution concentration80 mg/mL belimumab
Reconstitution volume, 120-mg vial1.5 mL Sterile Water for Injection, USP
Reconstitution volume, 400-mg vial4.8 mL Sterile Water for Injection, USP
Intravenous dilution volume250 mL, or 100 mL for patients weighing 40 kg or less
Maximum belimumab concentration in infusion bag4 mg/mL

Frequently asked questions

What is BENLYSTA indicated to treat?

BENLYSTA is indicated for patients 5 years of age and older with active systemic lupus erythematosus (SLE) or active lupus nephritis who are receiving standard therapy.

How is BENLYSTA administered intravenously?

The recommended intravenous dosage is 10 mg/kg at 2-week intervals for the first 3 doses and at 4-week intervals thereafter, administered as an infusion over 1 hour.

What are common adverse reactions with BENLYSTA?

Common adverse reactions include nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, pharyngitis, and injection site reactions.

Can live vaccines be given with BENLYSTA?

No, live vaccines should not be given concurrently with BENLYSTA.

Download PDF (2.6 MB)

More GLAXOSMITHKLINE Manuals


View all GLAXOSMITHKLINE manuals →